Activity of pyocin S2 against Pseudomonas aeruginosa biofilms

Karen Smith; Laura Martin; Angela Rinaldi; Ranjith Rajendran; Gordon Ramage; Daniel Walker

doi:10.1128/AAC.05714-11

Activity of pyocin S2 against Pseudomonas aeruginosa biofilms

Karen Smith, Laura Martin, Angela Rinaldi, Ranjith Rajendran, Gordon Ramage, Daniel Walker^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

41 Citations (Scopus)

Abstract

In cystic fibrosis patients, chronic lung infection with Pseudomonas aeruginosa and the associated decline in lung function are the major cause of mortality. In this report, we show that pyocin S2 displays potent activity against P. aeruginosa biofilms, thus representing a potentially improved therapeutic option. Using an invertebrate model of P. aeruginosa infection, we also show that pyocin S2 is highly active in vivo.

Original language	English
Pages (from-to)	1599-1601
Number of pages	3
Journal	Antimicrobial Agents and Chemotherapy
Volume	56
Issue number	3
Early online date	14 Feb 2012
DOIs	https://doi.org/10.1128/AAC.05714-11
Publication status	Published - Mar 2012
Externally published	Yes

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Documents and Links

10.1128/AAC.05714-11

Cite this

@article{9ee9bf48740c4e7786480195af956b17,

title = "Activity of pyocin S2 against Pseudomonas aeruginosa biofilms",

abstract = "In cystic fibrosis patients, chronic lung infection with Pseudomonas aeruginosa and the associated decline in lung function are the major cause of mortality. In this report, we show that pyocin S2 displays potent activity against P. aeruginosa biofilms, thus representing a potentially improved therapeutic option. Using an invertebrate model of P. aeruginosa infection, we also show that pyocin S2 is highly active in vivo.",

author = "Karen Smith and Laura Martin and Angela Rinaldi and Ranjith Rajendran and Gordon Ramage and Daniel Walker",

year = "2012",

month = mar,

doi = "10.1128/AAC.05714-11",

language = "English",

volume = "56",

pages = "1599--1601",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "3",

}

TY - JOUR

T1 - Activity of pyocin S2 against Pseudomonas aeruginosa biofilms

AU - Smith, Karen

AU - Martin, Laura

AU - Rinaldi, Angela

AU - Rajendran, Ranjith

AU - Ramage, Gordon

AU - Walker, Daniel

PY - 2012/3

Y1 - 2012/3

N2 - In cystic fibrosis patients, chronic lung infection with Pseudomonas aeruginosa and the associated decline in lung function are the major cause of mortality. In this report, we show that pyocin S2 displays potent activity against P. aeruginosa biofilms, thus representing a potentially improved therapeutic option. Using an invertebrate model of P. aeruginosa infection, we also show that pyocin S2 is highly active in vivo.

AB - In cystic fibrosis patients, chronic lung infection with Pseudomonas aeruginosa and the associated decline in lung function are the major cause of mortality. In this report, we show that pyocin S2 displays potent activity against P. aeruginosa biofilms, thus representing a potentially improved therapeutic option. Using an invertebrate model of P. aeruginosa infection, we also show that pyocin S2 is highly active in vivo.

U2 - 10.1128/AAC.05714-11

DO - 10.1128/AAC.05714-11

M3 - Article

C2 - 22183174

AN - SCOPUS:84863412234

SN - 0066-4804

VL - 56

SP - 1599

EP - 1601

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 3

ER -

Activity of pyocin S2 against Pseudomonas aeruginosa biofilms

Abstract

ASJC Scopus subject areas

UN SDGs

Documents and Links

Fingerprint

Cite this